[New targets and drugs for treatment of advanced renal cell carcinoma].
Conventional immunotherapeutic approaches have failed to achieve fundamental benefits for clinical outcome of patients with advanced metastatic renal cell carcinoma (MRCC). New, encouraging substances have gained broad access to the field of oncology and have already shown most promising preliminary results in patients with MRCC. Of mayor interest are antibodies and (receptor) tyrosine kinase inhibitors that are targeted against growth-factor receptors (of vascular endothelial and/or tumor cells). Single or multi-drug regimens are under way and are soon to be marketed.
Rohde
D
D
Urologische Klinik des Klinikums Darmstadt. detlef.rohde@klinikum-darmstadt.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D020794:Receptor Protein-Tyrosine Kinases